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a b s t r a c tIn this article we review the existing fertility preservation options for women diagnosed with Turner syndrome and provide practical
guidelines for the practitioner. Turner syndrome is the most common sex chromosome abnormality in women, occurring in approximately
1 in 2500 live births. Women with Turner syndrome are at extremely high risk for primary ovarian insufﬁciency and infertility. Although
approximately 70%-80% have no spontaneous pubertal development and 90% experience primary amenorrhea, the remainder might
possess a small residual of ovarian follicles at birth or early childhood. The present challenge is to identify these women as early in life as is
possible, to allow them to beneﬁt from a variety of existing fertility preservation options. To maximize the beneﬁts of fertility preservation,
all women with Turner syndrome should be evaluated by an expert as soon as possible in childhood because the vast majority will have
their ovarian reserve depleted before adulthood. Cryopreservation of mature oocytes and embryos is a proven fertility preservation
approach, and cryopreservation of ovarian tissue is a promising technique with a growing number of live births, but remains investiga-
tional. Oocyte cryopreservation has been performed in children with Turner syndrome as young as 13 years of age and ovarian tissue
cryopreservation in affected prepubertal children. However, current efﬁcacy of these approaches is unknown in this cohort. For those who
have already lost their ovarian reserve, oocyte or embryo donation and adoption are strategies that allow fulﬁllment of the desire for
parenting. For those with Turner syndrome-related cardiac contraindications to pregnancy, use of gestational surrogacy allows the pos-
sibility of biological parenting using their own oocytes. Alternatively, gestational surrogacy can serve to carry pregnancy resulting from the
use of donor oocytes or embryos, if needed.
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AdoptionIntroduction
Sixty-ﬁve years have passed since Ford et al1 reported
the association of a 45,X cell line with the phenotypic
ﬁndings that had been described 21 years earlier by Henry
Turner.2 Turner syndrome (TS) is one of the most common
chromosomal disorders, occurring in approximately 1 in
2500 newborn female infants.3 In normal circumstances a
female infant is born with approximately two million oo-
cytes within her ovaries, yet this is not the case in female
infants with TS, who are born with markedly fewer.3 How
do oocytes develop during embryonic life before birth, andThe authors indicate no conﬂicts of interest.
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chromosomes? In the female fetus, progenitors of oocytes
arise outside of the embryonic tissue that will become the
ovary, migrate along the dorsal mesentery from the region
of the junction of the allantois and yolk sac, populate the
indifferent gonad, and undergo rapid ampliﬁcation.4 Hu-
man primordial germ cells have been detected in the yolk
sac wall from three to four weeks postconception, in the
hind gut epithelium fromweek four, and in the genital area
from week ﬁve. Evidence suggests that chemotactic mole-
cules might guide these primordial germ cells to the gonad
and adhesion molecules present on their surface appear to
play a role in their migration.5 Newer estimates of the
number of primordial follicles at birth have been provided
by Mamsen et al,6 who studied 53 human ovaries obtained
at the time of elective pregnancy termination. The number
of germ cells increased from a mean of 7,200 atlished by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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determined using stereological techniques with an optical
dissector. This quantity then decreases to approximately
2,000,000 at birth and 400,000 at puberty.7 The mechanism
of this loss appears to be primarily apoptosis.8
Embryos bearing a 45,X karyotype have a high incidence
of in utero mortality and studies by Singh and Carr of 45,X
fetuses revealed the presence of germ cells in the early
genital ridges in normal numbers.9 However, by midg-
estation, their numbers were diminished signiﬁcantly. A
high incidence of follicle apoptosis, determined using ter-
minal deoxynucleotidyl transferase deoxyuridine
triphosphatase nick-end labeling assay, has been reported,
compared with that of a normal karyotype. Modi et al10
studied 16 normal fetal ovaries and four from 45,X fetuses
at 15-20 weeks' gestation. Semiquantitative measurements
revealed 3-7% terminal deoxynucleotidyl transferase
deoxyuridine triphosphatase nick-end labeling-positive
cells in normal ovaries versus 50%-70% in 45,X ovaries.
These results are consistent with accelerated germ cell
apoptosis in individuals with a 45, X karyotype.
There is considerable variability between individuals
regarding the size of this pool of primordial follicles. This
might, in part, because of variation between women during
the process that leads to follicular atresia, but might also
reﬂect the presence of sex chromosome aneuploidy at the
level of the ovaries, that might not be apparent in a leuko-
cyte karyotype. If the ovary is populated by two populations
of oogonia, one containing two X chromosomes (46,XX) and
one missing an X chromosome (45,X; ie, a mosaic karyo-
type), the number of oocytes at birth will be substantially
greater than seen in ovaries of a single line of 45,X. The pool
of primordial follicles in 46,XX/45,X mosaics might then be
large enough for a young woman to undergo menarche and
normal pubertal development.11 Invariably, however, these
women will exhaust their supply of primordial follicles at a
faster rate than age-comparable women with a normal
46,XX genotype, and are destined to undergo premature
ovarian insufﬁciency (POI).3
Integrity of the long arm of the X chromosome is
required for maintaining fertility. Quilter et al12 analyzed
the X chromosome using array comparative genomic hy-
bridization, documenting copy number variants in 15 of 42
women with POI. The majority was found in Xq. Mercer
et al13 studied 20 women who were missing a part of the
long arm of the X chromosome (Xq) using array compara-
tive genomic hybridization. Clinical features of TS were only
seen in a minority of women in their study, and they
commonly presented with abnormalities of menstruation
and fertility. The larger terminal deletions were associated
with a higher incidence of POI that occurred at younger
ages. Recently, Hook and Warburton14 reanalyzed the data
on the frequency of karyotypes at various stages of life
associated with TS, and found evidence of a high incidence
of cryptic mosaicism in 45,X individuals with TS. The
method of ascertainment of the cases, as well as the varying
sensitivity of the markers used and number of cells
analyzed were important determinants in detecting cryptic
sex chromosome mosaicism. The classic TS then appears to
be one end of a spectrum of ovarian dysfunctions associatedwith deletions and duplications of regions of the X chro-
mosome and occult mosaicism associated with loss of pri-
mordial germ cells leading to POI.
Although its physiologic role is not fully elucidated, anti-
M€ullerian hormone (AMH) is the best endocrine marker of
the size of the population of the dynamic reserve pool of
small antral follicles within the ovaries.15 AMH is a member
of the transforming growth factor-b family and is secreted
by granulosa cells of primary and small antral follicles, but
neither primordial nor larger-growing follicles.16 AMH
concentrations in the small antral follicles of human ovaries
have been found to be nearly three orders of magnitude
higher than in the follicular ﬂuid of preovulatory follicles.17
In female mice, evidence has shown that AMH functions as
an inhibitor of primordial follicle recruitment.18
Visser et al19 studied AMH levels in girls and adolescents
with TS. They found detectable AMH levels in 21.9% of these
girls, the results correlating with karyotypes. AMH was
detected in 77% of girls with 45,X/46,XX karyotypes, but in
only 10% of those with 45,X karyotypes. Hagen et al per-
formed longitudinal studies of serum AMH levels in 926
healthy women and 172 with TS, and found evidence that
AMH is a promising marker of ovarian function in healthy
girls and TS patients.20 It is apparent that a subset of girls
with TS possesses a small residual of ovarian follicles at
birth or early childhood. These would be further lost in late
childhood and early puberty, and most of these girls will
exhibit a mosaic karyotype. The present challenge is to
identify these girls as early in life as is possible, to allow
them to beneﬁt from a variety of existing fertility preser-
vation options.
Fertility Preservation Strategies
Spontaneous conceptions are rarely described in women
with TS and infertility attributed to lack of or exhausted
ovarian reserve is the norm.21 The reproductive phenotype
of TS is variable for a given genotype.19,20 Ovarian dysgen-
esis is commonly encountered in the setting of full 45,X
genotype and use of donated oocytes or embryos can allow
a chance for a successful conception.22 In contrast, varying
degrees of ovarian function can be retained for varying time
intervals in those with the 45,X/46,XX mosaic genotype,
although POI is unfortunately inevitable. It is in this latter
subgroup of young women with TS that salvage of existing
viable oocytes with the application of assisted reproductive
technologies is plausible. Herein, we review the currently
available and experimental techniques to preserve fertility
in females diagnosed with TS (Fig. 1).
Oocyte Cryopreservation
Although ovarian primordial follicle reserve might be
depleted well before puberty in nearly all TS girls with
nonmosaic karyotype, in mosaic cases and depending on
the degree of mosaicism, ovarian reserve might persist for a
variable period after menarche.24 However, because the
reserve would be low and the depletion of this reserve
would still occur at an accelerated rate, most might still not
reach adulthood with sufﬁcient ovarian reserve. It is
Fig. 1. A proposed algorhythmic approach to decision-making for fertility preservation in females diagnosed with Turner syndrome. For prepubertal girls with sufﬁcient ovarian
reserve, expert experience dictates utility of serial serum anti-M€ullerian hormone (AMH) assessments to delay intervention to a postpubertal age so that oocyte cryopreservation
can be considered. Serum AMH level of less than 2 ng/mL corresponds to levels in the lower quartile for girls aged 5-13 years of age.23 In postpubertal girls, because the risk of
follicle loss is extremely high and can proceed at a fast pace, we recommend fertility preservation regardless of the initial AMH.
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possible after menarche in these girls.
Although ovarian stimulation followed by oocyte
retrieval and cryopreservation have been reported in adults
with TS,25 the utility of this technology for the peri-
pubescent population had not been studied until recently.
Oktay et al have reported on successful oocyte cryopreser-
vation in postpubertal childrenwith mosaic TS.26,27 In these
reports, three girls aged 13-15 years with mosaic TS were
identiﬁed to have decreased ovarian reserve according to
serum AMH hormone measurements and antral follicle
counts on ultrasound examinations. Ovarian stimulation
was achieved with the use of recombinant follicle-
stimulating hormone (FSH) and later during stimulation
with luteinizing hormone (LH) supplementation in the form
of humanmenopausal gonadotropins or recombinant LH, in
an antagonist cycle. Because of the relative immaturity of
the function of the hypothalamus-pituitary-ovarian axis, LH
levels might be oversuppressed after the initiation of
gonadotropin-releasing hormone (GnRH) antagonist use.
For this reason Oktay and Bedoschi26 supplemented the
stimulation with LH to achieve adequate steroidogenesis.
Daily gonadotropin doses ranged from 225 to 300 IU.
Ovarian response to stimulation was monitored using a
combination of serial transabdominal ultrasound exami-
nations and serum estradiol measurements during ovarian
stimulation. Oocyte maturation was triggered either with
recombinant human chorionic gonadotropin, highly puri-
ﬁed human chorionic gonadotropin, or leuprolide acetate
34 hours before the retrieval. Oocyte retrievals were per-
formed transvaginally with general anesthesia. On average,
7-19 oocytes were retrieved, of which 4-10 were matureand cryopreserved. In one case, two cycles of oocyte cryo-
preservation were performed in a 14-year-old girl one year
apart; notably, mature oocyte yield decreased from 8 to 4 in
the second cycle, possibly because of the rapid decline in
ovarian reserve.27
These young girls, and their parents, were closely eval-
uated for physical and psychosocial suitability for the pro-
cedure before being accepted to the ovarian stimulation and
oocyte freezing program. This included a physical exami-
nation, preoperative evaluation by the anesthesiologist, and
counseling of parents and the child by the physician.
Others have also reported cryopreservation of in vitro
matured oocytes; immature oocytes were obtained during
an ovarian cryopreservation procedure.28 As will be dis-
cussed later, this creates another opportunity for oocyte
cryopreservation without ovarian stimulation, especially in
girls who undergo ovarian tissue harvesting for cryopres-
ervation. However, the pregnancy potential of in vitro-
matured oocytes from harvested ovarian tissue has not
been shown in women with or without TS, hence the po-
tential beneﬁt of this approach is unknown.
The ﬁrst birth attributable to use of cryopreserved and
thawed oocyte in humans was reported in 1986.29 Consid-
ered “experimental” for nearly three decades, reﬁnements
of the vitriﬁcation freezing protocols over the past decade
have signiﬁcantly advanced the ﬁeld. Oocyte cryopreser-
vation is now considered an established procedure in adults
and is increasingly being offered to and used by reproduc-
tive age women before initiation of gonadotoxic therapy for
the management of cancerous and noncancerous condi-
tions.30,31 However, the success rates of oocyte cryopreser-
vation in TS girls has not been shown. Depending on the
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fertilization or will develop with a normal karyotype
because a fraction will be missing the X chromosome.
However, technologies such as preimplantation genetic
screening have entered into routine use and embryos that
originate from the stored oocytes can be screened for nu-
merical chromosomal abnormalities. In addition, similar
genetic assessment can be accomplished using polar body
biopsy in oocytes.32 Because of these technological ad-
vances in oocyte and embryo screening, it is anticipated
that at least a fraction of oocytes frozen from TS girls should
lead to successful pregnancies.
However, despite the existing technology and potential
for applicability and utilization of oocyte-freezing early in
reproductive life as a fertility preserving strategy for TS pa-
tients, one cannot disregard possible oocyte aneuploidy and
risk therein to the progeny. Experience related to quantita-
tive ovarian response to exogenous gonadotropins is also
limited, and data on qualitative aspects of oocytes retrieved
in this population do not exist. Financial and emotional costs
attributed to the possible freezing of genetically abnormal
oocytes harvested from ovaries of womenwith TS cannot be
trivialized and until the safety of autologous oocytes is
established, oocyte cryopreservation by women with TS
should be offered only with careful oversight and an un-
derstanding that resulting embryos should be offered pre-
implantation genetic diagnosis to test for the genetic
normalcy of the progeny. However, the latter might not al-
ways be feasible because of cost, religious or ethical issues.
Maternal oocyte donation and cryopreservation for
subsequent use by a TS daughter is a plausible strategy for
girls with evidence of POI.33 Such an approach, however,
creates potential ethical concerns because the egg donor
would be the biological parent of her grandchild. Sibling-to-
sibling oocyte donation is a less tenuous and a more
acceptable alternative. Careful psychosocial evaluation of all
participants and of the family dynamics is warranted when
a mother-child or sibling-sibling egg donation approach is
being considered for preservation of procreative potential.
In summary, oocyte cryopreservation appears to be the
most viable option for girls with TS who have experienced
menarche and are endocrinologically and psychologically
mature enough to undertake the processes involved. We
recommend that all postmenarchal girls with TS be evalu-
ated for ovarian reserve assessment and patients and fam-
ilies counseled regarding oocyte cryopreservation as a
viable fertility preservation option.
Ovarian Tissue Cryopreservation
Ovarian tissue cryopreservation is a fertility preservation
technique, which is still considered experimental in
adults.34 The process involves surgical removal of a part or
all of an ovary, typically undertaken laparoscopically in an
outpatient setting; pieces of the outer layer (cortex) of the
removed ovarian tissue (which harbors the primordial fol-
licles that make up the ovarian reserve) are then cry-
opreserved for future use. Because ovarian reserve is already
low in girls with TS, it is recommended to remove as much
tissue as possible, typically an entire ovary. When thepatient is ready to attempt fertility, the cryopreserved pieces
of ovarian tissues are then thawed followed by auto-
transplantation back into the patient. A variety of anatom-
ical sites have been tried for autotransplantation including
the ovarian fossae in the pelvis (orthotopic) and under the
skin of an easily accessible area such as the forearm.35,36 The
ﬁrst successful ovarian transplantation with cryopreserved
and thawed tissue was reported in 2000 by Oktay and Kar-
likaya37 and resulted in restoration of hormonal function in
a previously menopausal woman. The subsequent decade
witnessed pregnancies resulting from these procedures
with the current total of reported pregnancies standing at
more than 40.38 It is important to appreciate that thus far, all
of these pregnancies with the exception of a recent case
report,39 resulted from use of ovarian tissue that was har-
vested from and subsequently transferred back to adult
women who chose ovarian tissue cryopreservation as a
fertility preserving strategy in the setting of medical di-
agnoses such as cancer or other medical conditions. Data on
efﬁciency of this approach in girls or women with TS are
lacking. Demeestere et al39 recently reported a live birth
when ovarian tissue, cryopreserved at the patient's age of
13 years, was autotransplanted during adulthood. The latter
established that ovarian tissue will be functional regardless
of the age that the tissuewas cryopreserved. As such, the full
biological development of ovaries are complete during the
third trimester of pregnancy and potentially even a
newborn ovary can produce follicles and ovulate when
proper hormonal signals are received.40 A good clinical
example of this is central precocious puberty in girls with
ovulation that occurs at a very young age.41
The foregoing information offers hope for girls with TS
who cannot wait until menarche to undergo ovarian stim-
ulation for the purpose of egg harvesting and subsequent
cryopreservation. Because the ovarian reserve can be lost
even during the very ﬁrst few years of life in full TS cases,
ovarian tissue cryopreservation might be the only, albeit
experimental, option for this population. Although ovarian
reserve evaluation might be difﬁcult in children younger
than the age of 5 years,20 a combination of serum FSH,
inhibin-B, AMH, and antral follicle counts on ultrasound
might provide useful information.24,26
Hreinsson et al reported that primordial follicles can be
found in ovarian tissue collected for cryopreservation from
mosaic and nonmosaic patients with TS in girls up to the age
of 17 years.42 In a larger study, the same group later re-
ported that ovarian biopsy was feasible in 47 of the 57 girls
and that in 15 of the 57 cases (26%), there were follicles in
the tissue pieces analyzed histologically. Furthermore, fol-
licle yield varied according to genotype, being evident in 6
of 7 cases (86%) of 46,XX/45,X mosaicism, in 6 of 22 with
structural chromosomal abnormalities (27%), and in 3 of 28
with 45,X karyotype (10.7%). Follicles were evident in bio-
psied ovarian tissue in 8 of 13 girls (62%) with spontaneous
menarche, and 11 of 19 of those who exhibited signs of
spontaneous puberty (58%). The 12- to 16-year-old age
group had the highest proportion of girls with evidence of
ovarian follicles on biopsied tissue. Normal FSH and AMH
concentrations for age and pubertal stage were more
frequent in girls with tissue evidence of follicles.43
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not guarantee that ovarian cryopreservation will be suc-
cessful, because the number of primordial follicles will be
much reduced in tissues cryopreserved from girls with TS
and the success of ovarian cryopreservation and trans-
plantation will depend on the number of oocytes present in
the transplanted tissue. Unless ovarian tissue is cry-
opreserved at very early ages, success of this technology for
girls with TS might be limited.
In summary, ovarian tissue cryopreservation can be
offered to girls with TS who are found to have adequate
ovarian reserve but who cannot wait until sufﬁcient
maturity to undergo oocyte cryopreservation. The promise
of this technology for girls with TS is at present hypothet-
ical, because no girl with TS who has undertaken this
approach thus far has returned for autotransplantation of
the previously cryopreserved ovarian tissue. The probability
of success of this approach is unknown and this option re-
mains experimental at the current time.
Embryo Cryopreservation
The promise of procreative success attributable to the
use of cryopreserved embryos far exceeds that offered by
frozen oocytes.44 Indeed, in some centers, live birth rates
after transfer of cryopreserved embryos are comparable
with rates achieved using fresh embryo transfer cycles.19
Protocols and processes involved up to the step of oocyte
collection are identical for oocyte and embryo freeze cycles.
However, beyond the step of oocyte retrieval, an immediate
access to sperm (either from a partner or a sperm donor) is a
requisite, which thus limits applicability of an efﬁcacious
option for fertility preservation to the postpubertal girls and
unpartnered young women diagnosed with TS. As with
oocyte freezing, medical and ethical concerns regarding
genetic normality of embryos resulting from fertilization of
oocytes retrieved from TS patients remains. Thus, for pa-
tients with TS who have identiﬁed a sperm source, elective
embryo cryopreservation as a fertility preservation strategy
should be offered under oversight with available preim-
plantation genetic diagnosis45 of the embryos before
transfer to test the genetic normalcy of the progeny.
Practical Issues and Patient Counseling for Fertility
Preservation in TS
One of the key determinants of success in fertility pres-
ervation for girls with TS is early referral to a fertility
specialist. Because of the rapid and accelerated decline in
ovarian reserve unique to this population, these girls should
be evaluated as early in postnatal life as possible. For the
nonmosaic patients, in whom ovarian reserve can be
depleted within the ﬁrst few years of life, this referral
should occur as soon as a diagnosis is made, even in infancy.
For the mosaic patients, an expedient approach is also
recommended but it might be possible to defer fertility
preservation until postmenarchal ages.
Karyotypic diagnosis must be established as soon as
possible. Although interpretability of ovarian reserve
markers in the TS population, particularly in theprepubescent girls, can be challenging, ovarian reserve
assessment should be undertaken using well validated
biomarkers (FSH, LH, estradiol, inhibin-B, AMH, and the
antral follicle count). Serum AMH norms have been estab-
lished for children and adults, and these levels are reliable
after the age of 5 years.20 In addition, ovarian volume and
antral follicle assessment might be helpful in older children.
Increased FSH levels in the presence of undetectable AMH
levels, the absence of visible antral follicles, and evidence of
streak ovaries indicate that ovarian failure has already
occurred, which makes the probability of yield for oocyte or
ovarian tissue cryopreservation highly unlikely.
Recommendations
Discussion of fertility preservation options is advised at
the earliest for any girl with TS; this might be at the time of
diagnosis, even when the diagnosis is arrived at during in-
fancy or childhood. Serial assessment of ovarian reserve
markers can be undertaken. In prepubertal girls with
mosaic TS who have a low percentage of cells with 45,X
karyotype relative to 46,XX and when AMH levels are not
inappropriately low for age (levels in the lower quartile for
age23), one of the authors (K.O.) uses frequent (every 2-
3 months) AMH monitoring to determine the time of
intervention. When AMH levels begin to show a decline on
two consecutive measurements, fertility preservation
might be considered. This approach might enable girls with
TS to further mature physically and psychosocially, and
become more compliant with procedures related to oocyte
cryopreservation instead of being limited to the currently
experimental ovarian tissue cryopreservation option.
If the ovarian reserve assessment indicates an age-
inappropriate decline in ovarian reserve in girls with
mosaic TS, and regardless of ovarian reserve in the non-
mosaic TS population, we recommend consideration of
fertility preservation at the earliest age possible.
For those who are sexually and or psychosocially imma-
ture or unable to tolerate ovarian stimulation procedures,
ovarian cryopreservation might be recommended under
experimental, institutional review board-approved pro-
tocols. In addition toobtaining an institutional reviewboard-
approved consent from the parents, verbal assent for the
proceduremust additionally be obtained fromchildren older
than nine years of age. The consent form should adequately
explain that currently the success of ovarian cryopreserva-
tionand transplantationcannotbequantiﬁed ingirlswithTS.
In postmenarchal girls, typically 13 years of age or older
and developmentally mature enough to tolerate ovarian
stimulation, oocyte cryopreservation should be offered.
Although the procedure is no longer considered experi-
mental in adults, a human subjects and institutional review
board-approved consent is still strongly encouraged for this
procedure to be undertaken in the pediatric population. At a
minimum, parents and children should be provided with a
detailed written consent form that explains the potential
limitations including the lack of TS-speciﬁc success rates
with this procedure. Embryo cryopreservation can be
considered in similar circumstances for those rare women
with TS who have reached adulthood with sufﬁcient
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those who are willing to use donor sperm.
Pregnancy in TS
Pregnancy with Autologous Oocytes
Between 2% and 5% of TS women are able to conceive
spontaneously, although these pregnancies are more likely
to occur in women with mosaic karyotypes, rather than full
monosomy X.46,47 They are reported to have higher than
normal rates of chromosomal abnormalities and rates of
miscarriage as high as 50%.48,49 Congenital and chromo-
somal abnormalities have been identiﬁed in approximately
50% of babies born to women with TS and this is thought to
be because of an inherited imbalance in genetic regula-
tion.50 For this reason, cycling mosaic TS women might
consider prenatal testing or even in vitro fertilization (IVF)
with preimplantation genetic testing to avoid aneuploidy
before embryo transfer. Additionally, girls and women with
TS are at an increased risk for POI, which thus shortens the
available time for natural conception for the affected pop-
ulation. Women who consider fertility should be offered
referral to reproductive endocrinologists and/or infertility
specialists for consultations about the family building op-
tions available to them that include use of donor oocytes or
embryos and of IVF with autologous oocytes.
IVF and Pregnancy with Donor Oocytes
For most patients with TS, the preferred option for
childbearing that offers the highest likelihood of success is
pregnancy with donor oocytes. Despite the use of donor
oocytes, miscarriage rates in resulting pregnancies among
TS recipients are slightly higher compared with the general
donor oocyte recipient population.21 Although the exact
cause of this increase in miscarriage risk is unclear, and
might reﬂect a surveillance bias, reduced uterine receptivity
from prolonged hypoestrogenism and relatively hypoplastic
uteri have been suggested as plausible mechanisms.48,49,51
Pregnancy Risks and Screening in TS
Obstetrical and Maternal Cardiovascular Risks
Pregnancies in women with TS are more likely to be
complicated by thyroid dysfunction, obesity, diabetes, and
hypertensive disorders, including pre-eclampsia (up to
40%).49,51 Low birth weight, intrauterine growth restriction,
preterm labor, and preterm delivery are also more likely in
pregnancies in women with TS.22,50
The well known cardiovascular strains of pregnancy,
including a 50% greater cardiac output, can signiﬁcantly
exacerbate underlying abnormalities such as congenital
heart disease, mostly left-sided disorders, which is recog-
nized in up to 50% of womenwith TS.52e54 In addition to the
pre-existing cardiac anomalies, women with TS have con-
nective tissue defects, which predispose them to aortic root
dissection, a catastrophic complication that is well recog-
nized to complicate pregnancies in women with TS and
carries a higher mortality rate. Overall, maternal mortalityin TS women has been reported to be as high as 1%-2%,
which is 100-200 times greater than in the general
population.47,52,55
Preconception cardiac evaluation to include measure-
ment of the aortic size index (in which aortic size di-
mensions are adjusted for body surface area) is strongly
recommended for any woman with TS who is contem-
plating pregnancy; an aortic size index greater than 2 cm/
m2 is considered a contraindication for pregnancy because
of the well-recognized higher risk of maternal mortality
secondary to aortic dissection in this population.56 Aortic
dissections might also occur postpartum (20%),56 and hence
close surveillance should continue after delivery.
Beyond the risk of cardiovascular detriment, pregnancy
in women with TS poses additional challenges. Renal
anomalies are present in up to 30%-40% of women with TS
with predisposition to development of hydronephrosis or
obstructive nephropathy in pregnancy.47,57 Hypothyroid-
ism, diabetes, and celiac diseasedall more frequently
encountered in women with TS compared with genetically
normal age-comparable womendmight ﬁrst manifest or
worsen during pregnancy.45
In conclusion, the occurrence of pregnancy in women
with TS poses unique challenges with attending risks that
include maternal death. Careful prepregnancy planning is
strongly endorsed. Prepregnancy management should
include cardiac evaluation and prepregnancy counseling by
a multidisciplinary team of specialists that includes cardi-
ologists, infertility specialists, genetic counselors, and ex-
perts in maternal-fetal medicine. With careful intra- and
postpregnancy vigilance and monitoring under the care of a
dedicated multidisciplinary team, the risks of maternal
morbidity and mortality can be mitigated and render the
attainment of a healthy pregnancy a real possibility for
women with TS.
Gestational Surrogacy for Women with TS
Gestational surrogacy (GS) entails the planned pregnancy
of a woman carried on behalf of another woman. Because of
the known potential cardiac and medical complications of
TS, GS is a reasonable and advisable alternative to pregnancy
in countries and in states in the United States that legally
allow it. GS might also provide an opportunity for women
with TS to be biological parents of their own children. Even
patientswith anormal cardiac evaluationmight be at risk for
cardiovascular complications that arise during the third
trimester of pregnancy or postpartum. Therefore, the
American Society of Reproductive Medicine recommends
that all patients with TS should be counseled about GS and
adoption as alternatives to pregnancy.56 Gametes can be
autologous or donated, especially in the case of POI.
In the United States, GS using fresh nondonor embryos
comprised approximately 1% of all assisted reproductive
technology (ART) cycles in 2012.58 The American Society of
Reproductive Medicine recommends GS for indications
including those of medical conditions that either prevent a
woman from carrying a pregnancy or those that impart
signiﬁcant risk of morbidity or mortality to the woman or
fetus.59 In women with TS, indications include major
K. Oktay et al. / J Pediatr Adolesc Gynecol 29 (2016) 409e416 415cardiovascular risks and those due to uterine abnormalities
as a result of decreased endometrial receptivity or long-
standinghypoestrogenism (aspreviouslymentioned).48,51,60
In all cases it is advised that the indications be well docu-
mented in the patient'smedical record.59 Recommendations
for speciﬁc medical tests have also been published and
psychosocial evaluation and education are advised for the
genetic parents and gestational surrogate.59 Both genetic
parents and gestational surrogates must be of legal age and
medically screened for presence or risk of infectious diseases
and carcinoma. Gestational surrogates should also be
counseled about the risks of pregnancy.
Although limited data are available for pregnancy and
live birth rates for women with TS,21,46 published data for
pregnancy outcomes of GS (whether autologous or donor
oocytes or embryos) are largely lacking. Thus, studies that
address pregnancy outcomes in this speciﬁc patient popu-
lation are needed so that women with TS will be better
informed about their reproductive options.
Adoption as a Family Building Option for Women with TS
In 2000, there were a total of 2,058,915 adopted children
living in the United States, corresponding to 2.5% of all
children.61,62 There are three kinds of domestic adoption in
the United States: state-licensed public agency adoptions,
private agency adoptions, and independent adoptions,
which involve the direct placement of a child through a
mediating agency or attorney.61 Adoption agencies provide
connections between children in need of a home, pregnant
women who wish to place a child with an adoptive family,
and prospective adoptive parents. Agencies typically assess
theparental capabilities of prospective adoptive families and
assist in the legal process of the adoption including appli-
cations to the court for legal adoptions. All adoption agencies
have requirements that mandate that prospective parents
meet certain criteria to be eligible to adopt a child.63 The
initial step in the eligibility process is typically a home study,
and most states require additional background checks and
probationary placement periods along with age and health
requirements thereafter. Just as adoption agency structures
are varied, preferences, policies, and requirements regarding
prospective parents differ considerably across agency lines.
Although some prospective families have had difﬁculties
with adoption because of health requirements (eg, cancer
survivors), there are no documented cases of a womanwith
TS being restricted from adoption.
International adoptions might be available to individuals
who pursue adoption in the United States, however, recent
restrictions and regulatory issues have caused a sharp
decline in international adoptions in the United States. At its
peak in 2004, there were 23,000 children from other
countries adopted by US families.64 The most recent ﬁgures
for international adoption in 2012 show a little more than
10,000 adoptions. The top ﬁve countries from which chil-
drenwere adopted in 2012 include China, Ukraine, Ethiopia,
Russia, and South Korea.
For womenwith TS who desire to be parents, adoption is
a viable option and one that has been pursued by many
womenwith TS. The need to weigh multiple factors such asthe low rates of spontaneous pregnancy, and potential
health risks of pregnancy to the mother and genetic out-
comes of the fetus coupled with highly personal desires
such as the wish to carry a pregnancy and/or the want for a
biological child and future parenting goals can result in
complex decisions. Such decisions are best made with input
from a personal physician, a reproductive endocrinologist, a
partner, and family.Summary and Conclusions
Women with TS are at extremely high risk for POI and
infertility. There are existing techniques, albeit some still in
the experimental realm, that can offer preservation of
fertility potential for some girls with TS, provided timely
consideration is entertained. To maximize the beneﬁts of
fertility preservation, all girls with TS should be evaluated
by an expert as soon as possible in childhood because most
will have their ovarian reserve depleted before adulthood.
For those who have already lost their ovarian reserve, donor
oocytes, donated embryos, and adoption are strategies that
can allow fulﬁllment of desire for parenting. For those with
TS-related cardiac contraindications to pregnancy, the
utility of GS can allow the possibility of biological parenting
through use of their own oocytes; alternatively, GS can
serve to carry pregnancy resulting from the use of donor
oocytes or embryos.Acknowledgments
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